Jun Li

Jun Li

Auto-generated profile, based on publicly available information

Jun Li

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
RARehan Akbani
Rehan Akbani
PNPatrick Kwok Shing Ng
Patrick Kwok Shing Ng
HWHenrica M. J. Werner
Henrica M. J. Werner
MSMaria Shahmoradgoli
Maria Shahmoradgoli
FZFan Zhang
Fan Zhang
GMGordon B. Mills
Gordon B. Mills
Protein levels and function are poorly predicted by genomic and transcriptomic analysis of patient tumours. Therefore, direct study of the functional proteome has the potential to provide a wealth of information that complements and extends genomic, epigenomic and transcriptomic analysis in The Cancer Genome Atlas (TCGA) projects. Here we use reverse-phase protein arrays to analyse 3,467 patient samples from 11 TCGA ‘Pan-Cancer’ diseases, using 181 high-quality antibodies that target 128 total proteins and 53 post-translationally modified proteins. The resultant proteomic data are integrated with genomic and transcriptomic analyses of the same samples to identify commonalities, differences, emergent pathways and network biology within and across tumour lineages. In addition, tissue-specific signals are reduced computationally to enhance biomarker and target discovery spanning multiple tumour lineages. This integrative analysis, with an emphasis on pathways and potentially actionable proteins, provides a framework for determining the prognostic, predictive and therapeutic relevance of the functional proteome.

14 September 2015 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JLJun Li
Jun Li
LHLeng Han
Leng Han
PRPaul Roebuck
Paul Roebuck
LDLixia Diao
Lixia Diao
LLLingxiang Liu
Lingxiang Liu
HLHan Liang
Han Liang
Long noncoding RNAs (lncRNA) have emerged as essential players in cancer biology. Using recent large-scale RNA-seq datasets, especially those from The Cancer Genome Atlas (TCGA), we have developed “The Atlas of Noncoding RNAs in Cancer” (TANRIC; http://bioinformatics.mdanderson.org/main/TANRIC:Overview), a user-friendly, open-access web resource for interactive exploration of lncRNAs in cancer. It characterizes the expression profiles of lncRNAs in large patient cohorts of 20 cancer types, including TCGA and independent datasets (>8,000 samples overall). TANRIC enables researchers to rapidly and intuitively analyze lncRNAs of interest (annotated lncRNAs or any user-defined ones) in the context of clinical and other molecular data, both within and across tumor types. Using TANRIC, we have identified a large number of lncRNAs with potential biomedical significance, many of which show strong correlations with established therapeutic targets and biomarkers across tumor types or with drug sensitivity across cell lines. TANRIC represents a valuable tool for investigating the function and clinical relevance of lncRNAs in cancer, greatly facilitating lncRNA-related biologic discoveries and clinical applications. Cancer Res; 75(18); 3728–37. ©2015 AACR.

15 September 2013 in Nature Methods
Verified
Journal Article
Open access
PDF file
JLJun Li
Jun Li
YLYiling Lu
Yiling Lu
RARehan Akbani
Rehan Akbani
ZJZhenlin Ju
Zhenlin Ju
PRPaul L Roebuck
Paul L Roebuck
HLHan Liang
Han Liang
Represents a powerful approach to understand the pathophysiology and therapy of cancer. However, comprehensive cancer proteomic data have been relatively limited. As a part of The Cancer Genome Atlas (TCGA) Project and other efforts, we have generated protein expression

1 October 2015 in Cancer Cell
Verified
Journal Article
Closed access
LHLeng Han
Leng Han
LDLixia Diao
Lixia Diao
SYShuangxing Yu
Shuangxing Yu
XXXiaoyan Xu
Xiaoyan Xu
JLJie Li
Jie Li
HLHan Liang
Han Liang

3 February 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
YYYang Yang
Yang Yang
LHLeng Han
Leng Han
YYYuan Yuan
Yuan Yuan
JLJun Li
Jun Li
NHNainan Hei
Nainan Hei
HLHan Liang
Han Liang
Prognostic genes are key molecules informative for cancer prognosis and treatment. Previous studies have focused on the properties of individual prognostic genes, but have lacked a global view of their system-level properties. Here we examined their properties in gene co-expression networks for four cancer types using data from ‘The Cancer Genome Atlas’. We found that prognostic mRNA genes tend not to be hub genes (genes with an extremely high connectivity), and this pattern is unique to the corresponding cancer-type-specific network. In contrast, the prognostic genes are enriched in modules (a group of highly interconnected genes), especially in module genes conserved across different cancer co-expression networks. The target genes of prognostic miRNA genes show similar patterns. We identified the modules enriched in various prognostic genes, some of which show cross-tumour conservation. Given the cancer types surveyed, our study presents a view of emergent properties of prognostic genes.

5 February 2020 in Nature Genetics
Verified
Journal Article
Open access
PDF file
YYYuan Yuan
Yuan Yuan
YJYoung Seok Ju
Young Seok Ju
DKDongik Kim
Dongik Kim
JLJun Li
Jun Li
YWYumeng Wang
Yumeng Wang
HLHan Liang
Han Liang
Mitochondria are essential cellular organelles that play critical roles in cancer. Here, as part of the International Cancer Genome Consortium/The Cancer Genome Atlas Pan-Cancer Analysis of Whole Genomes Consortium, which aggregated whole-genome sequencing data from 2,658 cancers across 38 tumor types, we performed a multidimensional, integrated characterization of mitochondrial genomes and related RNA sequencing data. Our analysis presents the most definitive mutational landscape of mitochondrial genomes and identifies several hypermutated cases. Truncating mutations are markedly enriched in kidney, colorectal and thyroid cancers, suggesting oncogenic effects with the activation of signaling pathways. We find frequent somatic nuclear transfers of mitochondrial DNA, some of which disrupt therapeutic target genes. Mitochondrial copy number varies greatly within and across cancers and correlates with clinical variables. Co-expression analysis highlights the function of mitochondrial genes in oxidative phosphorylation, DNA repair and the cell cycle, and shows their connections with clinically actionable genes. Our study lays a foundation for translating mitochondrial biology into clinical applications.